Lineage Cell Therapeutics Inc (AMEX:LCTX)
$ 0.6126 0.0052 (0.86%) Market Cap: 133.88 Mil Enterprise Value: 103.92 Mil PE Ratio: 0 PB Ratio: 1.74 GF Score: 61/100

Lineage Cell Therapeutics Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript

Jun 22, 2021 / 05:20PM GMT
Release Date Price: $2.74 (+2.24%)
Dane Leone
Raymond James & Associates, Inc. - Analyst

Great. Thanks, everyone, for joining us for the next session here at Raymond James 2021 Human Health Innovation Conference.

Really excited to have with me for a fireside chat, Brian Culley, CEO of Lineage Cell Therapeutics; doing a lot of exciting things but have had a number of interesting clinical updates recently around dry AMD geographic atrophy program that is an incredibly large unmet need. So new treatments are definitely of the highest importance here.

Maybe for the audience that doesn't know the Lineage Cell Therapeutics story as well, you -- Brian, if you can provide just a little bit of background of yourself and an overview of the Company.

Brian Culley
Lineage Cell Therapeutics, Inc. - CEO

Well, thanks, Dane. It's certainly our pleasure to be participating today.

I started in the lab -- I was a lab coat-wearing bench scientist for many years at places like Scripps Research and Neurocrine Biosciences, and then through business development eventually became a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot